[go: up one dir, main page]

HK1195770A1 - Amorphous solid salts of cobicistat (gs-9350) (cobicistat)(gs-9350) - Google Patents

Amorphous solid salts of cobicistat (gs-9350) (cobicistat)(gs-9350)

Info

Publication number
HK1195770A1
HK1195770A1 HK14109190.3A HK14109190A HK1195770A1 HK 1195770 A1 HK1195770 A1 HK 1195770A1 HK 14109190 A HK14109190 A HK 14109190A HK 1195770 A1 HK1195770 A1 HK 1195770A1
Authority
HK
Hong Kong
Prior art keywords
cobicistat
amorphous solid
solid salts
salts
amorphous
Prior art date
Application number
HK14109190.3A
Other languages
English (en)
Chinese (zh)
Inventor
Joanna M Koziara
Anne Luong
Keiko Sujino
Richard Yu
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of HK1195770A1 publication Critical patent/HK1195770A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28Radicals substituted by nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)
HK14109190.3A 2011-05-02 2014-09-11 Amorphous solid salts of cobicistat (gs-9350) (cobicistat)(gs-9350) HK1195770A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161481509P 2011-05-02 2011-05-02
PCT/US2012/035871 WO2012151165A1 (fr) 2011-05-02 2012-04-30 Sels solides amorphes

Publications (1)

Publication Number Publication Date
HK1195770A1 true HK1195770A1 (en) 2014-11-21

Family

ID=46086061

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14109190.3A HK1195770A1 (en) 2011-05-02 2014-09-11 Amorphous solid salts of cobicistat (gs-9350) (cobicistat)(gs-9350)

Country Status (9)

Country Link
US (1) US20140187771A1 (fr)
EP (1) EP2705027B1 (fr)
JP (1) JP2014513123A (fr)
AU (1) AU2012250890B2 (fr)
CA (1) CA2836768A1 (fr)
ES (1) ES2543923T3 (fr)
HK (1) HK1195770A1 (fr)
PT (1) PT2705027E (fr)
WO (1) WO2012151165A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015508822A (ja) * 2012-03-01 2015-03-23 ギリアード サイエンシーズ, インコーポレイテッド 噴霧乾燥製剤
JP2015534973A (ja) * 2012-10-23 2015-12-07 シプラ・リミテッド 抗レトロウイルス医薬組成物
US20160200716A1 (en) 2012-12-26 2016-07-14 Assia Chemical Industries Ltd. Cobicistat dichlohydrate salt
JP2016538312A (ja) * 2013-11-29 2016-12-08 マイラン ラボラトリーズ リミテッドMylan Laboratories Limited 非晶質のコビシスタットの固体分散体
CN105732538B (zh) * 2014-12-09 2018-04-13 杭州普晒医药科技有限公司 可比司他帕莫酸盐及其制备方法、药物组合物和用途
WO2016094011A1 (fr) * 2014-12-11 2016-06-16 Merck Sharp & Dohme Corp. Formes cristallines d'un antagoniste de ccr5
CN118286245A (zh) 2014-12-26 2024-07-05 埃莫里大学 N4-羟基胞苷和衍生物及与其相关的抗病毒用途
US10351556B2 (en) 2015-02-18 2019-07-16 Msn Laboratories Private Limited Process for the preparation of 1,3-thiazol-5-ylmethyl [(2R,5R)-5-{[(2s)-2-[(methyl{[2-(propan-2-yl)-1,3-thiazol-4YL] methyl} carbamoyl) amino]-4-(morpholin-4-yl)butanoyl]amino)-1,6-diphenylhexan-2-yl]carbamate
TW201728582A (zh) * 2016-01-28 2017-08-16 基利科學股份有限公司 結晶型
US10781192B2 (en) 2016-06-29 2020-09-22 Kezar Life Sciences Process of preparing a peptide epoxyketone immunoproteasome inhibitor, and precursors thereof
SMT202300145T1 (it) 2016-06-29 2023-07-20 Kezar Life Sciences Sali cristallini del peptide epossichetone inibitore dell’immunoproteasoma
AU2018378832B9 (en) 2017-12-07 2021-05-27 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CN110368370B (zh) * 2018-04-12 2022-08-12 湖南千金湘江药业股份有限公司 一种无定形半富马酸替诺福韦二吡呋酯片及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008010921A2 (fr) 2006-07-07 2008-01-24 Gilead Sciences, Inc. Modulateurs de propriétés pharmacocinétiques d'agents thérapeutiques
KR101577698B1 (ko) * 2007-02-23 2015-12-15 길리애드 사이언시즈, 인코포레이티드 치료제의 약동학적 특성의 조절제
AU2009242451C1 (en) * 2008-05-02 2017-05-18 Gilead Sciences, Inc. The use of solid carrier particles to improve the processability of a pharmaceutical agent
UA108738C2 (uk) * 2009-04-03 2015-06-10 Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки

Also Published As

Publication number Publication date
US20140187771A1 (en) 2014-07-03
NZ617351A (en) 2015-09-25
WO2012151165A1 (fr) 2012-11-08
CA2836768A1 (fr) 2012-11-08
JP2014513123A (ja) 2014-05-29
ES2543923T3 (es) 2015-08-25
AU2012250890A1 (en) 2013-05-02
PT2705027E (pt) 2015-09-11
EP2705027A1 (fr) 2014-03-12
AU2012250890B2 (en) 2015-05-28
EP2705027B1 (fr) 2015-06-03

Similar Documents

Publication Publication Date Title
IL286152A (en) Modified imidazopyridinyl-aminopyridine compounds
EP2742051A4 (fr) Forme amorphe de dolutegravir
HK1195770A1 (en) Amorphous solid salts of cobicistat (gs-9350) (cobicistat)(gs-9350)
HK1203196A1 (en) Substituted benzylpyrazoles
IL231725A0 (en) Crystalline forms of efitinib di-maleate
GB201001075D0 (en) Crystalline forms
GB201106395D0 (en) Compounds
ZA201309220B (en) Micelle-coated crystalline particles
GB201304499D0 (en) Carcainium Salts
ZA201306560B (en) Amorphous (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid
IL230976A0 (en) Crystalline forms of cvezitaxel
EP2760853A4 (fr) Nouveaux sels de l'alogliptine
PL2578595T3 (pl) Krystaliczna lewoizowalerylospiramycyna I
ZA201308160B (en) Crystalline salts of asenapine
GB201120644D0 (en) Herbicidal uses of compounds
SI2448945T1 (sl) Kristalinične oblike prasugrelovih soli
EP2601178A4 (fr) Sels de la lapatinib
EP2680843A4 (fr) Dérivés de composés amino-hétéroaryles substitués par des pyrazoles
GB201105659D0 (en) Compounds
HUP1000638A2 (en) Process for preparation of rosuvastatin salts
HK1193407A1 (en) Pyrrolidine-3-ylacetic acid derivative -3-
SG2014008858A (en) Crystallization methods
IL230977A (en) A crystalline form of relapaldib
EP2782902A4 (fr) Dérivés d'acide phénoxyisobutyrique
EP2768812A4 (fr) Sels d'addition d'acide de bosentan